BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Löhr JM, Hummel FM, Pirilis KT, Steinkamp G, Körner A, Henniges F. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur J Gastroenterol Hepatol. 2009;21:1024-1031. [PMID: 19352190 DOI: 10.1097/meg.0b013e328328f414] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ramakrishnan R, Singh AK, Singh S, Chakravortty D, Das D. Enzymatic Dispersion of Biofilms: An Emerging Biocatalytic Avenue to Combat Biofilm-Mediated Microbial Infections. Journal of Biological Chemistry 2022. [DOI: 10.1016/j.jbc.2022.102352] [Reference Citation Analysis]
2 Jiang Y, Wang J, Chen Y, Sun H, Dong Z, Xu S. Discrepancy Between Forceps Biopsy and Resection in Colorectal Polyps: A 1686 Paired Screening-Therapeutic Colonoscopic Finding. TCRM 2022;Volume 18:561-9. [DOI: 10.2147/tcrm.s358708] [Reference Citation Analysis]
3 Shrikhande SV, Prasad VGM, Domínguez-Muñoz JE, Weigl KE, Sarda KD. In vitro Comparison of Pancreatic Enzyme Preparations Available in the Indian Market. Drug Des Devel Ther 2021;15:3835-43. [PMID: 34522087 DOI: 10.2147/DDDT.S319949] [Reference Citation Analysis]
4 Ma P, Zhang Y, Liang Q, Yin Y, Wang S, Han R, Huo C, Deng H. Mifepristone (RU486) inhibits dietary lipid digestion by antagonizing the role of glucocorticoid receptor on lipase transcription. iScience 2021;24:102507. [PMID: 34308280 DOI: 10.1016/j.isci.2021.102507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Maev IV, Kucheryavyy YA, Gubergrits NB, Bonnacker I, Shelest EA, Janssen-van Solingen GP, Domínguez-Muñoz JE. Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS. Drugs R D 2020;20:369-76. [PMID: 33211277 DOI: 10.1007/s40268-020-00326-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Waldthaler A, Valente R, Arnelo U, Löhr JM. Endoscopic and Conservative Management of Chronic Pancreatitis and Its Complications. Visc Med 2019;35:98-108. [PMID: 31192243 DOI: 10.1159/000499611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. [PMID: 30962702 DOI: 10.2147/ceg.s168266] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 18.0] [Reference Citation Analysis]
8 Shandro BM, Nagarajah R, Poullis A. Challenges in the management of pancreatic exocrine insufficiency. World J Gastrointest Pharmacol Ther 2018; 9(5): 39-46 [PMID: 30397535 DOI: 10.4292/wjgpt.v9.i5.39] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
9 Trang T, Chan J, Graham DY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol 2014; 20(33): 11467-11485 [PMID: 25206255 DOI: 10.3748/wjg.v20.i33.11467] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
10 Löhr JM, Oliver MR, Frulloni L. Synopsis of recent guidelines on pancreatic exocrine insufficiency. United European Gastroenterol J 2013;1:79-83. [PMID: 24917944 DOI: 10.1177/2050640613476500] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
11 Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol 2013; 19(42): 7258-7266 [PMID: 24259956 DOI: 10.3748/wjg.v19.i42.7258] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 86] [Article Influence: 12.9] [Reference Citation Analysis]
12 Olesen AE, Brokjaer A, Fisher IW, Larsen IM. Pharmacological challenges in chronic pancreatitis. World J Gastroenterol 2013; 19(42): 7302-7307 [PMID: 24259961 DOI: 10.3748/wjg.v19.i42.7302] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
13 Yoo K. Medical Treatment of Chronic Pancreatitis. Korean J Med 2012;83:18. [DOI: 10.3904/kjm.2012.83.1.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73. [PMID: 21753892 DOI: 10.2147/ceg.s17634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 42] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kuhn RJ, Gelrud A, Munck A, Caras S. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. Adv Ther 2010;27:895-916. [PMID: 21086085 DOI: 10.1007/s12325-010-0085-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
16 Mössner J, Keim V. Pancreatic enzyme therapy. Dtsch Arztebl Int. 2010;108:578-582. [PMID: 21904592 DOI: 10.3238/arztebl.2011.0578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
17 Löhr J. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. European Journal of Gastroenterology & Hepatology 2010;22:636-7. [DOI: 10.1097/meg.0b013e328335ef64] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Löhr JM. In vitro comparative studies on pancreatic enzyme preparations. Aliment Pharmacol Ther 2010;31:160-1. [PMID: 20002030 DOI: 10.1111/j.1365-2036.2009.04154.x] [Reference Citation Analysis]